ClinicalTrials.gg
RecruitingNCT06143527Updated Oct 20, 2026

Safety of Cultured Allogeneic Adult Umbilical Cord or Placental Derived Mesenchymal Stem Cells for PCOS

A Phase 1 interventional study of Cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cells in Polycystic Ovary Syndrome (PCOS), Polycystic Ovary Syndrome and PCOS, sponsored by The Foundation for Orthopaedics and Regenerative Medicine. Recruiting at 2 sites in 2 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by The Foundation for Orthopaedics and Regenerative Medicine · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2023; still recruiting 3 years later.
Updated Oct 20, 2026First site in United StatesNo longer in Antigua and Barbuda+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 183 studies in Polycystic Ovary Syndrome with a site in United States — 32 open to participants now, 42 under way, 1 of them phase 3. Polycystic Ovary Syndrome · United States.

Planned enrollment
106th of 146
20 · median 39
Started
2023
with 9 others
Phase 1
26 of 183
10 open now
Primary completion
2027-11
later than 33 of 41 live
Registered
167th of 183
by date

Among the 183 studies in Polycystic Ovary Syndrome with a site in United States, this one is the 106th largest by planned enrollment of the 146 interventional ones that give a count, is one of 10 that started in 2023, is one of 26 in phase 1, reaches primary completion later than 33 of the 41 other live ones, and was the 167th registered.

Polycystic Ovary Syndrome

959 studies on the registry are indexed under Polycystic Ovary Syndrome; 176 are open to participants now.

Browse Polycystic Ovary Syndrome studies →

Open to participants now

32 of the 183 studies in Polycystic Ovary Syndrome with a site in United States are open now. Recruiting first, the newest first:

26 more — sign in →

All 32 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 120 Polycystic Ovary Syndrome studies recruiting now, 11 (9%) set no upper age limit and 106 (88%) stop at 75 or younger; 23 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 183 studies in Polycystic Ovary Syndrome with a site in United States, or all of them as a file.
02

Study summary

This trial will study the safety and efficacy of cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cells delivered intravenously for the treatment of Polycystic Ovary Syndrome.

Read the detailed description

Stem cell treatment has shown efficacy for PCOS in both human and animal studies. Complete resolution was seen of polycystic ovary syndrome (PCOS) in a young woman after a single intravenous injection of umbilical cord or placental derived mesenchymal stem cells (MSC). It is hypothesized that intravenous infusion of MSC can reduce or eliminate PCOS. Hormone levels and ultrasound will be checked 3,6 and 12 months after treatment.

03

Conditions studied

  • Polycystic Ovary Syndrome (PCOS)
  • Polycystic Ovary Syndrome
  • PCOS

Keywords

  • Polycystic Ovary Syndrome (PCOS)
  • Polycystic Ovary Syndrome
  • PCOS
  • Stem Cell
  • Stem Cells
  • Mesenchymal Stem Cells
  • Umbilical Cord Derived Mesenchymal Stem Cells
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ultrasound documented poly cystic ovary syndrome

Exclusion criteria

Exclusion Criteria:

  • Active infection
  • Active cancer
  • Chronic multisystem organ failure
  • Pregnancy
  • abnormalities on pre-treatment laboratory evaluation
  • Medical condition that would (based on the opinion of the investigator) compromise patient's safety
  • Continued drug abuse
  • Previous organ transplant
  • to sulfur
  • Inability to supply proper
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Treatment Group

    Intravenous infusion

    Biological: Cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cells

Interventions

  • BiologicalCultured allogeneic adult umbilical cord or placental derived mesenchymal stem cells

    Cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cells

06

What researchers measure

Primary outcomes

  1. Safety: Adverse Events

    Clinical monitoring of possible adverse events or complications

    Time frame: Four year follow-up

Secondary outcomes

  1. Efficacy: Global Improvement Score (GI)

    Ranging from 0 to 100%

    Time frame: Four year follow-up

07

Study locations

2 of 2 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2023 (actual). Primary completion is estimated for Nov 2027, 48 months after the start.

Of 27 phase 1 interventional studies under Polycystic Ovary Syndrome, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 147. This study's planned 48 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 16, 2023
First posted
Nov 22, 2023
StartActual
Nov 16, 2023
Primary completionEst.
Nov 16, 2027
CompletionEst.
Nov 16, 2027
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added, 2 sites removed — first site in United States; no longer in Antigua and Barbuda
Show 2 added (1 United States, 1 Greece)
  • Prodromos Stem Cell Institute · Naples, United States
  • Prodromos Stem Cell Institute · Athens, Greece
Show 2 removed
  • Medical Surgical Associates Center · St. John's, Antigua and Barbuda
  • Athens Beverly Hills Medical Group · Glyfáda, Greece
Oct 20, 2026
Interventions
Added Biological: Cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cells; removed Biological: AlloRx. Arm changed Treatment Group (AlloRx)→Treatment Group
Oct 20, 2026
Contact
Study contact changed: r•••@ismoc.net · •••6810→c•••@thepsci.com · •••6810. See the current contact
Oct 20, 2026
Title
Safety of Cultured Allogeneic Adult Umbilical Cord or Placental Derived Mesenchymal Stem Cells for PCOS
Oct 20, 2026
Show all 1 update
  1. Oct 20, 2026
    2 sites added, 2 sites removed — first site in United States; no longer in Antigua and Barbuda
    Show 2 added (1 United States, 1 Greece)
    • Prodromos Stem Cell Institute · Naples, United States
    • Prodromos Stem Cell Institute · Athens, Greece
    Show 2 removed
    • Medical Surgical Associates Center · St. John's, Antigua and Barbuda
    • Athens Beverly Hills Medical Group · Glyfáda, Greece
    Interventions Added Biological: Cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cells; removed Biological: AlloRx. Arm changed Treatment Group (AlloRx)→Treatment Group
    Contact Study contact changed: r•••@ismoc.net · •••6810→c•••@thepsci.com · •••6810. See the current contact
    Title Safety of Cultured Allogeneic Adult Umbilical Cord or Placental Derived Mesenchymal Stem Cells for PCOS
    + 4 other changes: verification date, description, data sharing statement and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06143527
Lead sponsor
The Foundation for Orthopaedics and Regenerative Medicine
Responsible party
Sponsor
First posted
Nov 22, 2023
Start date
Nov 16, 2023
Primary completion
Nov 16, 2027 (estimated)
Completion
Nov 16, 2027 (estimated)
Last update
Oct 20, 2026

Study contacts

Chadwick Prodromos, MD
Contact
care@thepsci.com
847-699-6810 ext. 202

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion